Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma

To evaluate the prognostic information of carbonic anhydrase (CA) IX expression in patients with renal cell carcinoma (RCC), as increased expression of CA IX is correlated with a worse prognosis in several malignancies.

[1]  K. Grankvist,et al.  Evaluation of CD31 (PECAM-1) Expression Using Tissue Microarray in Patients with Renal Cell Carcinoma , 2007, Tumor Biology.

[2]  K. Grankvist,et al.  Endoglin (CD105) expression in human renal cell carcinoma , 2006, BJU international.

[3]  J. Lam,et al.  Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. , 2005, The Journal of urology.

[4]  S. Signoretti,et al.  Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.

[5]  S. Horvath,et al.  Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. , 2005, The Journal of urology.

[6]  A. Harris,et al.  Hypoxia Inducible Carbonic Anhydrase IX, Marker of Tumour: Hypoxia, Survival Pathway and Therapy Target , 2004, Cell cycle.

[7]  R. Figlin,et al.  Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. , 2003, The Urologic clinics of North America.

[8]  R. Figlin,et al.  Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  A. Harris,et al.  Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer , 2003, British Journal of Cancer.

[10]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Charles C Wykoff,et al.  HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. , 2002, Cancer cell.

[12]  A. Harris,et al.  Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. , 2001, Cancer research.

[13]  A. Harris,et al.  Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. , 2001, Cancer research.

[14]  A. Harris,et al.  Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P Vaupel,et al.  Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. , 2001, Seminars in oncology.

[16]  W. Sly,et al.  Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. , 2001, The American journal of pathology.

[17]  P H Watson,et al.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.

[18]  S. Saga,et al.  MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas , 1999, British Journal of Cancer.

[19]  Kanda,et al.  MN/CA9 gene expression as a potential biomarker in renal cell carcinoma , 1999, BJU international.

[20]  M. Wei,et al.  Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  I. Tannock,et al.  The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. , 1998, British Journal of Cancer.

[22]  Holger Moch,et al.  The Heidelberg classification of renal cell tumours , 1997, The Journal of pathology.

[23]  E. Stanbridge,et al.  Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. , 1997, Cancer research.

[24]  M. Stifelman,et al.  Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. , 1997, Cancer research.

[25]  R. Kettmann,et al.  Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. , 1996, Genomics.

[26]  D. Ruiter,et al.  Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidney , 1986, International journal of cancer.

[27]  J. Schalken,et al.  Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. , 2004, Oncogene.

[28]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[29]  L. Sobin.  International Union Against Cancer , 2002 .

[30]  W. Sly,et al.  Human carbonic anhydrases and carbonic anhydrase deficiencies. , 1995, Annual review of biochemistry.

[31]  R. Colvin,et al.  Diagnosis and management of renal cell carcinoma A clinical and pathologic study of 309 cases , 1971, Cancer.

[32]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.